EP0756483B1 - Use of bisphophonates for inhibiting bone resorption following implantation of orthopedic prosthesis - Google Patents

Use of bisphophonates for inhibiting bone resorption following implantation of orthopedic prosthesis Download PDF

Info

Publication number
EP0756483B1
EP0756483B1 EP95916335A EP95916335A EP0756483B1 EP 0756483 B1 EP0756483 B1 EP 0756483B1 EP 95916335 A EP95916335 A EP 95916335A EP 95916335 A EP95916335 A EP 95916335A EP 0756483 B1 EP0756483 B1 EP 0756483B1
Authority
EP
European Patent Office
Prior art keywords
bone
alendronate
bone resorption
use according
implant device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP95916335A
Other languages
German (de)
French (fr)
Other versions
EP0756483A1 (en
Inventor
Ashley J. Yates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to EP01201914A priority Critical patent/EP1197213A3/en
Priority to SI9530651T priority patent/SI0756483T1/en
Publication of EP0756483A1 publication Critical patent/EP0756483A1/en
Application granted granted Critical
Publication of EP0756483B1 publication Critical patent/EP0756483B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the instant invention relates generally to the use of alendronate for the manufacture of a medicament to prevent periprosthetic bone loss in patients having an orthopedic implant device.
  • the failure rate increases exponentially with time so that many patients with an aging hip prosthesis (10 to 15 years), experience pain at the site of the implant and eventually require revision to the original procedure.
  • a hallmark of these patients is that at the time they develop pain and loosening of the joint they have markedly increased bone turnover, especially bone resorption, in the bone immediately adjacent to the implant.
  • bone scanning agents which are bisphosphonates tagged with technetium, are often taken up at very high concentrations in these areas indicating that there may well be significant targeting of bisphosphonates to the periprosthetic bone.
  • Bone turnover In normal growing bones, the mineral deposition exceeds the mineral resorption, whereas in certain pathological conditions, bone resorption exceeds bone deposition, for instance, due to malignancy or primary hyperparathyroidism, or in osteoporosis. In other pathological conditions the deposition of new bone may take place in undesirable amounts and areas leading to, e.g., heterotopic ossification, osteosclerosis, and Paget's disease which is a combination of an abnormal high bone resorption followed by an abnormal calcium deposition. With orthopedic implants, bone resorption may occur at an accelerated rate in the periprosthetic area leading to net bone loss.
  • Bisphosphonates are also known in the art as bone resorption inhibitors.
  • Alendronate 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium trihydrate is a known bone resorption inhibitor and is described in U.S. Patents 4,922,007 and 5,019,651 (Merck).
  • Clodronate (dichloromethylene)bisphosphonic acid disodium salt (Proctor and Gamble, is described in Belgium Patent 672,205 (1966) and its preparation is found in J. Org. Chem 32, 4111 (1967).
  • Tiludronate ([(4-chlorophenyl)thiomethylene]-bisphosphonic acid) (Sanofi) is described in U.S. Patent 4,876,248 issued October 24, 1989.
  • YM 175 [(cycloheptylamino)methylene]bisphosphonic acid, disodium salt) by Yamanouchi is described in U.S. Patent 4,970,335 issued November 13, 1990.
  • What is desired in the art is a therapy to optimally treat the bone resorption in the periprosthetic area of an implant device, i.e., the bone area which is in contact and close proximity to the device implant, to retard the loosening of the device and to alleviate the pain associated with this condition.
  • a bisphosphonate can be used in such patients for the prophylaxis and treatment of failure of joint prostheses, e.g., for the hip or knee.
  • Long term administration of a relatively low dose of alendronate can prevent the periprosthetic bone resorption process and thereby maintain the integrity of the total structure.
  • the treatment can be further extended to patients with symptomatic failure of a joint prostheses or internal fixation device.
  • Alendronate is able to reverse the loosening of a prosthesis once it has occurred, and there is also some alleviation of the bone pain which accompanies this complication of joint replacement.
  • alendronate for the manufacture of a medicament for treating and/or preventing (reducing the risk of) periprosthetic bone loss in a subject having an orthopedic implant device comprising administering to said subject a pharmaceutically effective dose of alendronate.
  • the Figure illustrates the effects of alendronate on bone resorption at different concentrations, on the rat bone marrow ablation model in which bone is regenerated in the voided regions of the bone.
  • the medicaments disclosed herein can be used to treat human subjects who have a prosthesis, i.e., a medical implant device.
  • the use according to the invention involves the administration of alendronate in an osteogenically effective amount to inhibit bone resorption in the periprosthetic bone area of a medical implant device.
  • peripheral bone area as used herein is meant the area of bone which is an contact with the medical implant device or in the immediate proximity thereof.
  • inhibiting bone resorption refers to prevention of bone loss, especially the inhibition of removal of existing bone either from the mineral phase and/or the organic matrix phase, through direct or indirect alteration of osteoclast formation or activity.
  • inhibitor of bone resorption refers to agents that prevent bone loss by the direct or indirect alteration of osteoclast formation or activity.
  • osteogenically effective means that amount which decreases the turnover of mature bone. As used herein, an osteogenically effective dose is also “pharmaceutically effective.”
  • subject refers to a living vertebrate animal such as a mammal in need of treatment, i.e., in need of periprosthetic bone repair.
  • the periprosthetic bone loss may arise in cases of systemic bone disease, as in osteoporosis (of any etiology), osteoarthritis, Paget's disease, osteomalacia, multiple myeloma and other forms of cancer.
  • treatment shall mean (1) providing a subject with an amount of alendronate sufficient to act prophylactically on periprosthetic bone to prevent the development of a weakened and/or unhealthy state; and/or (2) providing a subject with a sufficient amount of alendronate so as to alleviate or eliminate a disease state and/or the symptoms of a disease state in the area of periprosthetic bone.
  • the invention is useful for treating defects and disorders in the periprosthetic area of bone which result in a weakened structure and/or pain.
  • alendronate may be administered to the periprosthetic bone area systemically either orally and/or parenterally, including subcutaneous or intravenous injection. Additionally, the alendronate may be delivered in a slow release form from a suitable carrier.
  • the alendronate may be administered locally to the specific periprosthetic area in need of bone growth or repair.
  • the alendronate may be implanted directly at the site to be treated, for example, by injection or surgical implantation in a sustained-release carrier.
  • Suitable carriers include hydrogels, controlled- or sustained-release devices (e.g., an Alzet® minipump), polylactic acid, and collagen matrices.
  • telopeptide collagen containing particulate calcium phosphate mineral components such combinations of homologous or xenographic fibrillar atelopeptide collagen (for example, Zyderm® Collagen Implant, available from Collagen Corporation, Palo Alto, Calif.) with hydroxapatitetricalcium phosphate (HA-TCP, available from Zimmer, Inc., Warsaw, In.). It is presently preferred to administer implant compositions containing alendronate in a collagen/mineral mixture implant.
  • Alendronate delivered in sustained-release vehicles is useful for improving implant fixation, for example, for improving in growth of new bone into a metal prosthesis in joint reconstruction or orthopedic implants.
  • orthopedic implants can be coated with alendronate to enhance attachment of the implant device to the bone at the time of the implant operation.
  • implant devices may be coated with a alendronate as follows.
  • the alendronate is dissolved at a concentration in the range of 0.01 ⁇ g/ml to 200 mg/ml in phosphate-buffered saline (PBS) containing 2 mg/ml serum albumin.
  • PBS phosphate-buffered saline
  • the porous end of an implant is dipped in the solution and is airdried (or lyophilized) or implanted immediately into the bony site.
  • the viscosity of the coating solution is increased, if desired, by adding hyaluronate at a final concentration of 0.1 mg/ml to 100 mg/ml or by adding other pharmaceutically acceptable excipients.
  • the solution containing the alendronate is mixed with collagen gel or human collagen (e.g., Zyderm® Collagen Implant, Collagen Corp., Palo Alto, Calif.) to a final collagen concentration of 2 mg/ml to 100 mg/ml to form a paste or gel, which is then used to coat the porous end of the implant device.
  • the coated implant device is placed into the periprosthetic bony site immediately or is airdried and rehydrated with PBS prior to implanting, with the objective of maximizing new bone formation into and around the implant while minimizing the ingrowth of soft tissue into and around the implant site.
  • compositions of the invention which include alendronate for administration will generally include an osteogenically effective amount of alendronate to promote bone growth, in addition to a pharmaceutically acceptable excipient.
  • Suitable excipients include most carriers approved for parenteral administration, including water, saline, Ringer's solution, Hank's solution, and solutions of glucose, lactose, dextrose, ethanol, glycerol, albumin, and the like.
  • These compositions may optionally include stabilizers, antioxidants, antimicrobials, preservatives, buffering agents, surfactants, and other accessory additives.
  • the bisphosphonate inhibitor of bone resorption may also be delivered in a sustained release form from a suitable carrier.
  • a presently preferred vehicle comprises phosphate-buffered saline (PBS) or isotonic citrate buffer.
  • PBS phosphate-buffered saline
  • isotonic citrate buffer phosphate-buffered saline
  • Such formulations are generally known to those skilled in the art and are administered systemically to provide systemic treatment.
  • an effective dose for alendronate is about 1.5 to 3000 ⁇ g/kg per day of body weight and preferably about 10 ⁇ g/kg to about 200 ⁇ g/kg per day of body weight.
  • a particularly preferred dosage is 10 mg per day per person.
  • Effective doses for local administration will be about 0.001 ⁇ g to 1 mg per application site.
  • compositions according to the present invention containing alendronate may be prepared for use in the form of capsules or tablets or in solution for oral administration or for systemic use.
  • the compositions are advantageously prepared together with inert carriers such as sugars (saccharose, glucose, lactose), starch and derivatives, cellulose and derivatives, gums, fatty acids and their salts, polyalcohols, talc, aromatic esters.
  • Bisphosphonate drugs which prevent bone loss and/or add back lost bone can be evaluated in the ovariectomized rat.
  • This animal model is well established in the art (see, for example, Wronski, et al ., (1985) "Calcif. Tissue Int.” 37 :324-328; Kimmel, et al ., (1990) "Calcif. Tissue Int.” 46 :101-110; and Durbridge, et al ., (1990) "Calcif. Tissue Int.” 47 :383-387; these references are hereby incorporated in their entirety).
  • Wronski, et al ., ((1985) "Calcif. Tissue Int.” 43 :179-183)) describe the association of bone loss and bone turnover in the ovariectomized rat. Alendronate is active in this assay.
  • Cn-BV/TV% represents cancellous bone volume divided by total structure volume
  • SEM represents standard error of the-mean
  • ALN is alendronate
  • Fisher PLSD is a standard statistical least squares technique.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Dental Preparations (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed is a therapy for treating and for preventing periprosthetic bone loss by the administration of a bisphosphonate bone resorption inhibitor, e.g., alendronate, in patients who have an orthopedic implant device.

Description

FIELD OF THE INVENTION
The instant invention relates generally to the use of alendronate for the manufacture of a medicament to prevent periprosthetic bone loss in patients having an orthopedic implant device.
BACKGROUND OF THE INVENTION
A major problem with patients who have orthopedic implant devices or joint prosthesis, such as hip replacements, is that many of these begin to fail after five years or so from the time that they are inserted. The failure rate increases exponentially with time so that many patients with an aging hip prosthesis (10 to 15 years), experience pain at the site of the implant and eventually require revision to the original procedure. Although initially this was considered to be a result of fragmentation of the cement substances utilized in older hip prostheses, the problem continues to be observed even in the newer devices which do not rely on the use of cement. A hallmark of these patients is that at the time they develop pain and loosening of the joint they have markedly increased bone turnover, especially bone resorption, in the bone immediately adjacent to the implant. Evidence for this bone turnover can be seen from the fact that bone scanning agents, which are bisphosphonates tagged with technetium, are often taken up at very high concentrations in these areas indicating that there may well be significant targeting of bisphosphonates to the periprosthetic bone.
There is a need in the art for localized controlled/extended release dosage forms of bone growth promotant since in the United States, there are approximately 5 million fractures and 265,000 prosthetic implants per year. Of this population, there is about a 20-30% failure rate within five years of the operation, requiring a repeat surgery and device implant.
Normal bones are living tissues which undergo constant resorption and new bone formation, with the net effect of maintenance of a constant mineral balance. The dual process is commonly called "bone turnover". In normal growing bones, the mineral deposition exceeds the mineral resorption, whereas in certain pathological conditions, bone resorption exceeds bone deposition, for instance, due to malignancy or primary hyperparathyroidism, or in osteoporosis. In other pathological conditions the deposition of new bone may take place in undesirable amounts and areas leading to, e.g., heterotopic ossification, osteosclerosis, and Paget's disease which is a combination of an abnormal high bone resorption followed by an abnormal calcium deposition. With orthopedic implants, bone resorption may occur at an accelerated rate in the periprosthetic area leading to net bone loss.
Most of the currently available therapeutic agents for the treatment of osteoporosis, e.g., estrogens, act by reducing bone resorption in the osteoporotic patient. See the review article, "British Medical Bulletin" 46 (1), p. 94-112 (1990).
Bisphosphonates are also known in the art as bone resorption inhibitors.
Alendronate, 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium trihydrate is a known bone resorption inhibitor and is described in U.S. Patents 4,922,007 and 5,019,651 (Merck).
Clodronate, (dichloromethylene)bisphosphonic acid disodium salt (Proctor and Gamble, is described in Belgium Patent 672,205 (1966) and its preparation is found in J. Org. Chem 32, 4111 (1967).
Tiludronate, ([(4-chlorophenyl)thiomethylene]-bisphosphonic acid) (Sanofi) is described in U.S. Patent 4,876,248 issued October 24, 1989.
YM 175 ([(cycloheptylamino)methylene]bisphosphonic acid, disodium salt) by Yamanouchi is described in U.S. Patent 4,970,335 issued November 13, 1990.
BM 21.0995 (1-Hydroxy-3-(methylpentylamino)-propylidene-bisphosphonate) by Boehringer-Mannheim - is described in U.S. Patent 4,927,814 issued May 22, 1990.
A study by Proctor and Gamble (Norwich Eaton Pharmaceuticals) using risedronate, whose chemical name is sodium trihydrogen [1-hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonate, in combination with estrogen showed a positive effect on bone loss in ovariectomized rats (published in Abstracts 731 and 732 at the Fall 1992 ASBMR meeting in Minnesota).
The article, "J. Clin. Invest.", Jan. 1992, 89 (1), p. 74-78 by J. Chow et al., describes the effect of estrogen on ovariectomized rats in which bone resorption was suppressed by pamidronate whose chemical name is 3-amino-1-hydroxy propylidene-bisphosphonic acid disodium salt. They concluded that estrogen inhibits bone resorption and also stimulates bone formation.
Another Proctor and Gamble compound, piridronate, [2-(2-pyridinyl)ethylidene]-bisphosphonic acid, monosodium salt is described in USP 4,761,406 as having bone resorption inhibition activity.
The article, "Monatschefte" 99, 2016 (1968) by F. Kasparet describes the synthesis of etidronate, (1-hydroxyethylidene)-bisphosphonic acid, disodium salt, (Proctor and Gamble).
However, the above cited art does not suggest or describe the use of a bisphosphonate in situations to specifically prevent bone resorption in the periprosthetic bone area of an orthopedic implant device.
What is desired in the art is a therapy to optimally treat the bone resorption in the periprosthetic area of an implant device, i.e., the bone area which is in contact and close proximity to the device implant, to retard the loosening of the device and to alleviate the pain associated with this condition.
SUMMARY OF THE INVENTION
We have discovered that a bisphosphonate can be used in such patients for the prophylaxis and treatment of failure of joint prostheses, e.g., for the hip or knee. Long term administration of a relatively low dose of alendronate can prevent the periprosthetic bone resorption process and thereby maintain the integrity of the total structure.
The treatment can be further extended to patients with symptomatic failure of a joint prostheses or internal fixation device. Alendronate is able to reverse the loosening of a prosthesis once it has occurred, and there is also some alleviation of the bone pain which accompanies this complication of joint replacement.
By this invention there is provided the use of alendronate for the manufacture of a medicament for treating and/or preventing (reducing the risk of) periprosthetic bone loss in a subject having an orthopedic implant device comprising administering to said subject a pharmaceutically effective dose of alendronate.
BRIEF DESCRIPTION OF THE FIGURE
The Figure illustrates the effects of alendronate on bone resorption at different concentrations, on the rat bone marrow ablation model in which bone is regenerated in the voided regions of the bone.
DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS
The medicaments disclosed herein can be used to treat human subjects who have a prosthesis, i.e., a medical implant device.
The use according to the invention involves the administration of alendronate in an osteogenically effective amount to inhibit bone resorption in the periprosthetic bone area of a medical implant device.
By the term "periprosthetic bone area" as used herein is meant the area of bone which is an contact with the medical implant device or in the immediate proximity thereof.
The term "inhibition of bone resorption" as used herein refers to prevention of bone loss, especially the inhibition of removal of existing bone either from the mineral phase and/or the organic matrix phase, through direct or indirect alteration of osteoclast formation or activity. Thus, the term "inhibitor of bone resorption" as used herein refers to agents that prevent bone loss by the direct or indirect alteration of osteoclast formation or activity.
The term "osteogenically effective" as used herein means that amount which decreases the turnover of mature bone. As used herein, an osteogenically effective dose is also "pharmaceutically effective."
The term "subject" as used herein refers to a living vertebrate animal such as a mammal in need of treatment, i.e., in need of periprosthetic bone repair. The periprosthetic bone loss may arise in cases of systemic bone disease, as in osteoporosis (of any etiology), osteoarthritis, Paget's disease, osteomalacia, multiple myeloma and other forms of cancer.
The term "treatment" or "treating" as used herein shall mean (1) providing a subject with an amount of alendronate sufficient to act prophylactically on periprosthetic bone to prevent the development of a weakened and/or unhealthy state; and/or (2) providing a subject with a sufficient amount of alendronate so as to alleviate or eliminate a disease state and/or the symptoms of a disease state in the area of periprosthetic bone.
The invention is useful for treating defects and disorders in the periprosthetic area of bone which result in a weakened structure and/or pain.
In accordance with one method of use, alendronate may be administered to the periprosthetic bone area systemically either orally and/or parenterally, including subcutaneous or intravenous injection. Additionally, the alendronate may be delivered in a slow release form from a suitable carrier.
In accordance with another method of use, the alendronate may be administered locally to the specific periprosthetic area in need of bone growth or repair. Thus, the alendronate may be implanted directly at the site to be treated, for example, by injection or surgical implantation in a sustained-release carrier. Suitable carriers include hydrogels, controlled- or sustained-release devices (e.g., an Alzet® minipump), polylactic acid, and collagen matrices. Presently preferred carriers are formulations of atelopeptide collagen containing particulate calcium phosphate mineral components, such combinations of homologous or xenographic fibrillar atelopeptide collagen (for example, Zyderm® Collagen Implant, available from Collagen Corporation, Palo Alto, Calif.) with hydroxapatitetricalcium phosphate (HA-TCP, available from Zimmer, Inc., Warsaw, In.). It is presently preferred to administer implant compositions containing alendronate in a collagen/mineral mixture implant.
Alendronate delivered in sustained-release vehicles is useful for improving implant fixation, for example, for improving in growth of new bone into a metal prosthesis in joint reconstruction or orthopedic implants.
Alternatively, orthopedic implants can be coated with alendronate to enhance attachment of the implant device to the bone at the time of the implant operation.
In general, implant devices may be coated with a alendronate as follows. The alendronate is dissolved at a concentration in the range of 0.01 µg/ml to 200 mg/ml in phosphate-buffered saline (PBS) containing 2 mg/ml serum albumin. The porous end of an implant is dipped in the solution and is airdried (or lyophilized) or implanted immediately into the bony site. The viscosity of the coating solution is increased, if desired, by adding hyaluronate at a final concentration of 0.1 mg/ml to 100 mg/ml or by adding other pharmaceutically acceptable excipients. Alternatively, the solution containing the alendronate, is mixed with collagen gel or human collagen (e.g., Zyderm® Collagen Implant, Collagen Corp., Palo Alto, Calif.) to a final collagen concentration of 2 mg/ml to 100 mg/ml to form a paste or gel, which is then used to coat the porous end of the implant device. The coated implant device is placed into the periprosthetic bony site immediately or is airdried and rehydrated with PBS prior to implanting, with the objective of maximizing new bone formation into and around the implant while minimizing the ingrowth of soft tissue into and around the implant site.
Pharmaceutical formulations of the invention which include alendronate for administration will generally include an osteogenically effective amount of alendronate to promote bone growth, in addition to a pharmaceutically acceptable excipient. Suitable excipients include most carriers approved for parenteral administration, including water, saline, Ringer's solution, Hank's solution, and solutions of glucose, lactose, dextrose, ethanol, glycerol, albumin, and the like. These compositions may optionally include stabilizers, antioxidants, antimicrobials, preservatives, buffering agents, surfactants, and other accessory additives. The bisphosphonate inhibitor of bone resorption may also be delivered in a sustained release form from a suitable carrier.
A presently preferred vehicle comprises phosphate-buffered saline (PBS) or isotonic citrate buffer. A thorough discussion of suitable vehicles for parenteral administration may be found in E. W. Martin. "Remington's Pharmaceutical Sciences" (Mack Pub. Co., current edition sections relating to the excipient vehicles and formulating being incorporated herein by reference to disclose such). Such formulations are generally known to those skilled in the art and are administered systemically to provide systemic treatment.
The precise dosage of alendronate necessary will vary with the age, size, sex and condition of the subject, the nature and severity of the disorder to be treated, and the like; thus, a precise effective amount cannot be specified in advance and will be determined by the caregiver. However, appropriate amounts may be determined by routine experimentation with animal models, as described below. In general terms, an effective dose for alendronate is about 1.5 to 3000 µg/kg per day of body weight and preferably about 10 µg/kg to about 200 µg/kg per day of body weight. A particularly preferred dosage is 10 mg per day per person.
Effective doses for local administration will be about 0.001 µg to 1 mg per application site.
The pharmaceutical compositions according to the present invention containing alendronate may be prepared for use in the form of capsules or tablets or in solution for oral administration or for systemic use. The compositions are advantageously prepared together with inert carriers such as sugars (saccharose, glucose, lactose), starch and derivatives, cellulose and derivatives, gums, fatty acids and their salts, polyalcohols, talc, aromatic esters.
Some typical pharmaceutical formulations containing alendronate, 4-amino-1-hydroxybutane-1,1-diphosphonic acid monosodium salt trihydrate, are shown here below:
ALENDRONATE TABLETS (WHITE), 200 MG
COMPOSITION IN MG/TABLET
INGREDIENT 2.5 mg 5.0 mg 10.0 mg 40.0 mg
Alendronate 3.26 6.55 13.05 51.21
Lactose NF Anydrous 113.74 110.45 103.95 64.79
Microcrystalline Cellulose NF 80.0 80.0 80.0 80.0
Magnesium Stearate
Impalpable NF		 1.00 1.00 1.00 1.00
Croscarmellos Sodium NF
Type A		 2.00 2.00 2.00 2.00
OPERCOLATED CAPSULES
1 2
Alendronate mg 6.5 mg 2.5
Lactose 110.0 110.0
Avucek Ph101 80.0 80.0
Aldisol/NF Type A 2.0 2.0
Magnesium Stearate 1.0 1.0
Total Weight 202.5 Total Weight 197.5
EFFERVESCENT GRANULATES
Alendronate mg 5.0
Anhydrous Sodium Carbonate 12.0
Sodium Bicarbonate 63.0
Anhydrous Citric Acid 110.0
Sodium Saccharinate 5.0
Saccharose 493.0
Dehydrated Lemon Juice 55.0
Natural Essence of Lemon 2.0
Total Weight 748
FORMULATIONS SUITABLE FOR INJECTION
Alendronate mg 0.5 mg 1.00
Sodium Hydroxide 0.25 0.25
Sodium Chloride 8.40 16.30
Purified Water q h ml 1.0 ml 12.0
Bisphosphonate drugs which prevent bone loss and/or add back lost bone can be evaluated in the ovariectomized rat. This animal model is well established in the art (see, for example, Wronski, et al., (1985) "Calcif. Tissue Int." 37:324-328; Kimmel, et al., (1990) "Calcif. Tissue Int." 46:101-110; and Durbridge, et al., (1990) "Calcif. Tissue Int." 47:383-387; these references are hereby incorporated in their entirety). Wronski, et al., ((1985) "Calcif. Tissue Int." 43:179-183)) describe the association of bone loss and bone turnover in the ovariectomized rat. Alendronate is active in this assay.
EXAMPLE Alendronate Effects on Bone Formation and Resorbability of Bone Formed During Alendronate Treatment
To study the effects of alendronate during rapid bone formation, a modified bone marrow ablation model in the rat described in J. Bone Miner. Res. Vol. 8, pp. 379-388 (1993) by L. J. Suva et al., was used. In the rat, extraction of bone marrow (ablation) from a long bone results in rapid bone formation which fills 25% of the marrow cavity with cancellous bone (Cn) within 6 to 7 days. This bone is then fully resorbed (replaced) within the next 15 days. When rats were orally treated with 1, 2, 8 or 40 µg/kg alendronate day s.c. for 6 days, post-ablation, there was no difference in bone volume at 7 days (See the Figure), indicating that alendronate has no detectable effect on bone formation. In the Figure, Cn-BV/TV% represents cancellous bone volume divided by total structure volume; SEM represents standard error of the-mean; ALN is alendronate; Fisher PLSD is a standard statistical least squares technique. After treatment was stopped, the amount of bone remaining in the marrow cavity at the various doses was examined at 4, 14, 24 and 54 days later. For an alendronate dose of 1 µg/kg, bone was completely resorbed at 14 days, no different from controls. At 2 µg/kg/day, bone was also completely resorbed 24 days after cessation of treatment. At 8 and 40 µg/kg/day, bone was also resorbed, albeit more slowly, resulting in a retention of about 33% and 50%, respectively, at 54 days (See the Figure). These findings show that, at levels much higher than a human dose, there is no interference at all with bone formation in this model, and that bone formed at these doses is fully resorbable, albeit more slowly than occurs with lower doses.
This data is consistent with the method of administering alendronate to a patient's periprosthetic bone area to prevent bone resorption and a weakening at the site of the medical implant device. The slowing of the rate of bone resorption, but not its complete inhibition, is predicted to be associated with an improvement in the local bone balance in the periprosthetic bone which would provide greater integrity to the overall bone and prosthesis structure.

Claims (11)

  1. Use of alendronate for the manufacture of a medicament for treating and/or preventing periprosthetic bone resorption in a subject having an orthopedic implant device.
  2. Use of alenronate for the manufacture of a medicament for reversing the loosening of an orthopedic implant device.
  3. Use of alendronate for the manufacture of a medicament for retarding the loosening of an orthopedic implant device.
  4. Use according to any one of claims 1 to 3 wherein the subject is human.
  5. Use according to any one of claims 1 to 4 wherein the treatment is prophylactic.
  6. Use according to any one of claims 1 to 5 wherein said alendronate is administered by an oral dosage form.
  7. Use according to any one of claims 1 to 5 wherein said alendronate is administered parenterally.
  8. Use according to claim 7 wherein said alendronate is administered parenterally at the site of periprosthetic bone.
  9. Use according to any one of claims 1 to 8 wherein said alendronate is in the form of its monosodium salt.
  10. Use according to claim 9 wherein said alendronate is alendronate monosodium trihydrate.
  11. Use according to any one of claims 1 to 10 wherein said orthopedic implant device is a hip prosthesis.
EP95916335A 1994-04-21 1995-04-17 Use of bisphophonates for inhibiting bone resorption following implantation of orthopedic prosthesis Expired - Lifetime EP0756483B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01201914A EP1197213A3 (en) 1994-04-21 1995-04-17 Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis
SI9530651T SI0756483T1 (en) 1994-04-21 1995-04-17 Use of bisphophonates for inhibiting bone resorption following implantation of orthopedic prosthesis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US230670 1994-04-21
US08/230,670 US5646134A (en) 1994-04-21 1994-04-21 Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
PCT/US1995/004498 WO1995028936A1 (en) 1994-04-21 1995-04-17 Use of bisphophonates for inhibiting bone resorption following implantation of orthopedic prosthesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP01201914A Division EP1197213A3 (en) 1994-04-21 1995-04-17 Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis

Publications (2)

Publication Number Publication Date
EP0756483A1 EP0756483A1 (en) 1997-02-05
EP0756483B1 true EP0756483B1 (en) 2003-04-09

Family

ID=22866129

Family Applications (2)

Application Number Title Priority Date Filing Date
EP01201914A Withdrawn EP1197213A3 (en) 1994-04-21 1995-04-17 Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis
EP95916335A Expired - Lifetime EP0756483B1 (en) 1994-04-21 1995-04-17 Use of bisphophonates for inhibiting bone resorption following implantation of orthopedic prosthesis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP01201914A Withdrawn EP1197213A3 (en) 1994-04-21 1995-04-17 Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis

Country Status (29)

Country Link
US (3) US5646134A (en)
EP (2) EP1197213A3 (en)
JP (1) JPH09512268A (en)
CN (1) CN1078073C (en)
AT (1) ATE236641T1 (en)
AU (1) AU2374895A (en)
BG (1) BG63102B1 (en)
CA (1) CA2188030C (en)
CO (1) CO4370025A1 (en)
CZ (1) CZ305596A3 (en)
DE (1) DE69530293T2 (en)
DK (1) DK0756483T3 (en)
DZ (1) DZ1873A1 (en)
ES (1) ES2194050T3 (en)
FI (1) FI964213A (en)
HR (1) HRP950239A2 (en)
HU (1) HUT74911A (en)
IL (1) IL113361A (en)
MY (1) MY114265A (en)
NO (1) NO312124B1 (en)
NZ (1) NZ284295A (en)
PL (1) PL318552A1 (en)
PT (1) PT756483E (en)
RU (1) RU2161032C2 (en)
SK (1) SK133396A3 (en)
TW (1) TW406021B (en)
WO (1) WO1995028936A1 (en)
YU (1) YU25295A (en)
ZA (1) ZA953185B (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
EP0886521B1 (en) * 1996-02-14 2003-05-21 Itzhak Binderman Topical bisphosphonates for prevention of bone resorption
US6117856A (en) * 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
ID24096A (en) * 1997-07-22 2000-07-06 Merck & Co Inc METHODS FOR OBSTACLING BONE RESORTS
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
IT1296495B1 (en) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa USE OF BISPHOSPHONATES IN THE PREPARATION OF PHARMACEUTICAL FORMS FOR INTRAMUSCULAR ADMINISTRATION
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
TR200101546T2 (en) * 1998-12-04 2001-11-21 Roche Diagnostics Gmbh Using ibandronate to improve bone integration in internal prostheses.
EP1147773B1 (en) * 1998-12-25 2004-04-07 Yamanouchi Pharmaceutical Co. Ltd. Medicinal compositions for treating osseous lesion in multiple myeloma
WO2000064516A1 (en) * 1999-04-22 2000-11-02 Hydromed Sciences A Division Of Gp Strategies Corporation Controlled delivery of bisphosphonates
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
AU781068B2 (en) * 1999-08-19 2005-05-05 Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children), The Drug for treating fractures
WO2002004038A1 (en) * 2000-07-12 2002-01-17 Hopital Orthopedique De La Suisse Romande Active biocoating for bone implant
CH694935A5 (en) * 2000-07-26 2005-09-30 Straumann Holding Ag Oberflaechenmodifizierte implants.
WO2002040073A1 (en) * 2000-11-20 2002-05-23 Université De Genève Endosseous implant
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
DK1365769T3 (en) 2001-02-06 2011-05-16 Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital Drug for the treatment of osteonecrosis and for the treatment of patients at risk of developing osteonecrosis
US20040157798A1 (en) * 2001-04-03 2004-08-12 Little David Graham Drug for use in bone grafting
KR20020080018A (en) * 2001-04-10 2002-10-23 한국화학연구원 A controlled/sustained implant delivery containing bisphosphonate
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
MXPA04006027A (en) * 2001-12-21 2004-09-27 Procter & Gamble Method for the treatment of bone disorders.
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
WO2003093314A2 (en) * 2002-05-03 2003-11-13 Millenium Biologix Inc. Connective tissue stimulating peptides
US20040137058A1 (en) * 2002-07-09 2004-07-15 Katdare Ashok V. Effervescent bisphosphonate formulation
ES2561463T3 (en) * 2003-08-21 2016-02-26 Addbio Ab Implant device coated with bisphosphonate and method for it
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US7674454B2 (en) * 2004-03-06 2010-03-09 Innovata Limited Enzyme-prodrug therapy for prosthetic joint repair
KR100564628B1 (en) * 2004-06-16 2006-03-28 삼성전자주식회사 Split gate type flash mwmory device and method of manufacturing the same
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
WO2006100527A1 (en) * 2005-03-24 2006-09-28 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Effervescent tablet containing sodium alendronate and related use and process
US20070087052A1 (en) * 2005-10-19 2007-04-19 Katdare Ashok V Effervescent bisphosphonate formulation
FR2904784B1 (en) * 2006-08-10 2010-09-03 Surfactis Technologies PROCESS FOR RECOVERING METALLIC AND MINERAL SURFACES BY SELF-ASSEMBLED MONOMOUCHES OF BISPHOSPHONIC COMPOUNDS AND USES THEREOF
EP2136814A4 (en) * 2007-03-21 2012-05-30 Univ Duke Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
US8183225B2 (en) * 2007-11-08 2012-05-22 New York University Inhibition of bone resorption using medical implants containing adenosine receptor antagonists
SI2473172T1 (en) 2009-09-01 2015-07-31 Duke University Bisphosphonate compositions and methods for treating heart failure
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
CA2820019A1 (en) * 2010-12-06 2012-06-14 Effrx Pharmaceuticals Sa Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
US8858979B1 (en) 2011-01-28 2014-10-14 Clemson University Service induced byproducts for localized drug delivery in orthopaedic implants
CA2835340A1 (en) * 2011-05-27 2012-12-06 Ablynx Nv Inhibition of bone resorption with rankl binding peptides
US9949992B2 (en) 2011-11-16 2018-04-24 Duke University Bisphosphonate compositions and methods for treating and\or reducing cardiac dysfunction
RU2653627C1 (en) * 2016-11-09 2018-05-11 Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" Method for modeling aseptic aminobisphosphonate osteonecrosis of lower jaws in laboratory white rats

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446052A (en) * 1982-05-17 1984-05-01 The Procter & Gamble Company Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate
US4753652A (en) * 1984-05-04 1988-06-28 Children's Medical Center Corporation Biomaterial implants which resist calcification
CN1046853C (en) * 1988-01-20 1999-12-01 山之内制药株式会社 (Cycloalkyl amine) methylene di (phosphonic acid) and drug taking this compound as active component
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
EP0642519B1 (en) * 1992-05-29 2000-08-09 Procter & Gamble Pharmaceuticals Sulfur-containing phosponate compounds for treating abnormal calcium and phosphate metabolism
JPH08505142A (en) * 1992-12-23 1996-06-04 メルク エンド カンパニー インコーポレーテッド Bisphosphonate / estrogen therapy for treating and preventing bone loss
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
FI92465C (en) * 1993-04-14 1994-11-25 Risto Tapani Lehtinen A method for handling endo-osteal materials
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration

Also Published As

Publication number Publication date
NO964441L (en) 1996-10-18
DZ1873A1 (en) 2002-02-17
RU2161032C2 (en) 2000-12-27
JPH09512268A (en) 1997-12-09
US5646134A (en) 1997-07-08
IL113361A0 (en) 1995-07-31
SK133396A3 (en) 1997-05-07
CA2188030A1 (en) 1995-11-02
HU9602888D0 (en) 1996-12-30
NO964441D0 (en) 1996-10-18
NO312124B1 (en) 2002-03-25
BG63102B1 (en) 2001-04-30
EP1197213A2 (en) 2002-04-17
AU2374895A (en) 1995-11-16
PT756483E (en) 2003-07-31
US5891863A (en) 1999-04-06
DE69530293D1 (en) 2003-05-15
DE69530293T2 (en) 2004-02-05
ATE236641T1 (en) 2003-04-15
EP0756483A1 (en) 1997-02-05
CN1078073C (en) 2002-01-23
FI964213A0 (en) 1996-10-18
ZA953185B (en) 1995-12-27
HRP950239A2 (en) 1997-04-30
CZ305596A3 (en) 1997-06-11
HUT74911A (en) 1997-03-28
ES2194050T3 (en) 2003-11-16
IL113361A (en) 1999-11-30
BG100910A (en) 1998-03-31
WO1995028936A1 (en) 1995-11-02
DK0756483T3 (en) 2003-04-28
MY114265A (en) 2002-09-30
EP1197213A3 (en) 2002-09-25
CO4370025A1 (en) 1996-10-07
TW406021B (en) 2000-09-21
YU25295A (en) 1999-09-27
FI964213A (en) 1996-10-18
US5972913A (en) 1999-10-26
PL318552A1 (en) 1997-06-23
CN1146152A (en) 1997-03-26
NZ284295A (en) 2000-06-23
CA2188030C (en) 2003-07-29

Similar Documents

Publication Publication Date Title
EP0756483B1 (en) Use of bisphophonates for inhibiting bone resorption following implantation of orthopedic prosthesis
CA2151240A1 (en) Biophosphonate/estrogen therapy for treating and preventing bone loss
US5510370A (en) Parathyroid hormone and raloxifene for increasing bone mass
US5403829A (en) Use of bisphosphonates in endo-osteal bone surgery
EP0758241B1 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
AU5973496A (en) Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
WO2001049295A1 (en) Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification
US6399592B1 (en) Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
CA2353528C (en) Use of ibandronate for promoting osseointegration of endoprostheses
AU9745901A (en) Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis
AU2005203308A1 (en) Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis
AU3574799A (en) Use of biphosphonates for inhibiting bone resorption following implantation of orthopedic prosthesis
MXPA96004968A (en) Use of bisphosphonates to inhibit bone rebassion after the implantation of orthopedic protesis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961121

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 961121

17Q First examination report despatched

Effective date: 20000605

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/663 A

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Extension state: SI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20030422

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20030424

Year of fee payment: 9

Ref country code: DK

Payment date: 20030424

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20030425

Year of fee payment: 9

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20030429

Year of fee payment: 9

Ref country code: GR

Payment date: 20030429

Year of fee payment: 9

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20030514

Year of fee payment: 9

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20030516

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20030630

Year of fee payment: 9

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20030402209

Country of ref document: GR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2194050

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20040112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040417

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040417

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040419

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040430

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040430

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040430

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041018

BERE Be: lapsed

Owner name: *MERCK & CO. INC.

Effective date: 20040430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041103

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20041018

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20041101

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20050314

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20050401

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20050418

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20050429

Year of fee payment: 11

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20050121

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1009250

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060417

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060418

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060430

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061101

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20060417

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20061230

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20060418

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20030422

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060502

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070417